Percocet Pill — Competitive Intelligence Brief

Percocet Pill (Percocet Pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic combination. Area: Pain Management.

phase 3 Opioid analgesic combination Mu opioid receptor (primary); also delta and kappa opioid receptors Pain Management Small molecule

Target snapshot

Percocet Pill (Percocet Pill) — Rothman Institute Orthopaedics. Percocet combines oxycodone (an opioid agonist) and acetaminophen to provide pain relief through central nervous system depression and peripheral analgesic effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Percocet Pill TARGET	Percocet Pill	Rothman Institute Orthopaedics	phase 3	Opioid analgesic combination	Mu opioid receptor (primary); also delta and kappa opioid receptors
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Codeine with acetaminophen	Codeine with acetaminophen	Children's Hospitals and Clinics of Minnesota	marketed	Opioid analgesic combination	Mu opioid receptor (codeine); COX enzymes (acetaminophen)
Motrin and narcotic	Motrin and narcotic	Cape Fear Valley Health System	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (ibuprofen); mu, delta, and kappa opioid receptors (narcotic component)
lidocaine and sufentanil	lidocaine and sufentanil	RenJi Hospital	marketed	Local anesthetic and opioid analgesic combination	Voltage-gated sodium channels (lidocaine); mu opioid receptor (sufentanil)
metoprolol plus morphine	metoprolol plus morphine	Sahlgrenska University Hospital	marketed	Beta-blocker plus opioid analgesic combination	Beta-1 adrenergic receptor; mu-opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic combination class)

1. VA Office of Research and Development · 3 drugs in this class
2. Rothman Institute Orthopaedics · 2 drugs in this class
3. Labopharm Inc. · 2 drugs in this class
4. University of Rochester · 2 drugs in this class
5. Montefiore Medical Center · 2 drugs in this class
6. Maastricht University Medical Center · 2 drugs in this class
7. Henry Ford Health System · 1 drug in this class
8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
9. Albert Einstein College of Medicine · 1 drug in this class
10. Johnson & Johnson Taiwan Ltd · 1 drug in this class